Curriculum Vitae Maike Sonnenberg, PhD

Affiliation

Postdoctoral fellow at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Auerbachstr. 112
D-70376 Stuttgart
phone: ++49-711-8101 5691
fax: ++49-711-859295
email: maike.sonnenberg@ikp-stuttgart.de

Dr. rer. nat. Maike Sonnenberg

phone: ++49-711-8101 5691

maike.sonnenberg@ikp-stuttgart.de

Education and Professional Career

2000 - 2005	Study of biology, University of Hohenheim, Germany
2005	Diploma degree of biology, University of Hohenheim, Germany
2005 - 2009	PhD study: “Investigation of the influence of chemotherapy on cancer-associated fibroblasts in lung and breast carcinomas in vivo and in different ex vivo systems“ at Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (Prof. Dr. W. E. Aulitzky)
2005 - 2009	Fellowship Robert Bosch Gesellschaft für medizinische Forschung MbH
2008	AstraZeneca Scholar-in-Training Award, 99th Annual Meeting AACR, San Diego 2008: Maike Sonnenberg, Thomas E. Mürdter, Peter Fritz, Wolfgang Simon, Heiko van der Kuip, Walter E. Aulitzky. Chemotherapy affects tumor stroma. Proc Amer Assoc Cancer Res; 2008 Apr 12-16; [V 2581] oral presentation
2009	Doctoral degree of biology (PhD), Faculty of Natural Sciences, University of Hohenheim, Germany
2009	Sales representative at Marvecs GmbH, Ulm (Project work for AstraZeneca, Germany, Department of Oncology/Gynecology)
2009 to present	Postdoctoral fellow and biobanking project manager at Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

Selected References

Haubeiss S, Schmid JO, Muerdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE. Dasatinib reverses Cancer-associated Fibroblasts (CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of normal Fibroblasts. Molecular Cancer, 2010; 9:168 (FREE ARTICLE)

Sonnenberg M, van der Kuip H, Fritz P, Haubeiß S, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer 2008 Dec 11;8:364 (FREE ARTICLE)

Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE, van der Kuip H. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl negative cells. Oncogene 2008 Jul 17;27(31):4380-4

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clinical Cancer Research 2007 Jun 1; 13(11):3198-206 (FREE ARTICLE)

van der Kuip H, Murdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer. 2006 Apr 7;6:86 (FREE ARTICLE)